Search results
Results from the WOW.Com Content Network
CA 27.29 is a tumor marker for breast cancer. [1] It is a form of glycoprotein MUC1. [2] References ... This page was last edited on 4 November 2023, at 05:27 (UTC).
CA27.29: breast cancer [11] CA19-9: Mainly pancreatic cancer, but also colorectal cancer and other types of gastrointestinal cancer. [12] CA-125: Mainly ovarian cancer, [13] but may also be elevated in for example endometrial cancer, fallopian tube cancer, lung cancer, breast cancer and gastrointestinal cancer. [14] Calcitonin: medullary ...
CA 27.29 (aka BR 27.29) and CA 15-3 measure different epitopes of the same protein antigen product of the MUC1 gene seen in breast cancer. CA 27.29 has enhanced sensitivity and specificity compared to CA 15-3 and is elevated in 30% of patients with low-stage disease and 60 to 70% of patients with advanced-stage breast cancer.
CA 15-3, for Carcinoma Antigen 15-3, is a tumor marker for many types of cancer, most notably breast cancer. [1] [2] [3]It is derived from MUC1. [4] CA 15-3 and associated CA 27-29 are different epitopes on the same protein antigen product of the breast cancer-associated MUC1 gene.
CA 15-3; CA 27-29; CA 242 (tumor marker) CA19-9; Calcitonin; Cancer-associated fibroblast; Carcinoembryonic antigen; Carcinoembryonic antigen peptide-1; Cyclin B; D.
Tumor antigen is an antigenic substance produced in tumor cells, i.e., it triggers an immune response in the host. Tumor antigens are useful tumor markers in identifying tumor cells with diagnostic tests and are potential candidates for use in cancer therapy .
CA-125 was initially detected using the murine monoclonal antibody designated OC125. Robert Bast, Robert Knapp and their research team first isolated this monoclonal antibody in 1981. [28] The protein was named "cancer antigen 125" because OC125 was the 125th antibody produced against the ovarian cancer cell line that was being studied. [29]
Besides, the existence of blood-testis barrier and the lack of human leukocyte antigen (HLA) class I expression on the surface of germ cells prevent the immune system interacting with CT antigens proteins and recognizing it as invading structures. Thus, CT antigens can be regarded as essentially tumor-specific targets when they are expressed in ...